Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,006 questions · 3,171 findings · 607 reviews · Headline outcomes only

No studies found 411 · 13%GRADE not reported 153 · 4.8%Very low 968 · 30.5%Low 897 · 28.3%Moderate 589 · 18.6%High 153 · 4.8%

Intervention not reported

Angiotensin receptor blocker (high‐ versus medium‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus medium‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus medium‐ dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High‐ versus medium‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High vs low dose Systolic blood pressure · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

High vs low dose Diastolic blood pressure · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Intervention not reported

Angiotensin receptor blocker (high‐ versus low‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review

Amantadine vs placebo

Reduction in fatigue · people with fatigue in Guillain‐Barré syndrome

Amantadine showed no clear difference in reduction in fatigue of at least 1‐point on the Fatigue Severity… compared with placebo (low certainty).

1 finding from 1 review

Riluzole vs placebo

Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review

Physiotherapy and occupational therapy vs placebo

Short‐term (1 week) change in isolated movement, objective and subjective measures of speech production SARA. Scale from: 0 to 6. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review